Edward Lanphier

PROFESSIONAL

Edward Lanphier is serving as Advisor to the Chief Executive Officer of the Buck Institute for Research on Aging.  In June 2016, he retired from Sangamo BioSciences, Inc., where he was founder, President, Chief Executive Officer and a member of the Board of Directors since the company's inception in 1995. Mr. Lanphier has over thirty years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc.  From 1984 to 1986 Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc.  Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group.

EDUCATION

  • BA in biochemistry, Knox College

MEMBERSHIPS & AFFILIATIONS | AWARDS & HONORS

  • Member, Buck Advisory Council, Buck Institute for Research on Aging
  • Member, Board of Trustees, Buck Institute for Research on Aging
  • Member, Board of Trustees, Choate Rosemary Hall
  • Member, Board of Directors,  Biotechnology Institute
  • Member, Dean’s Advisory Board, University of Michigan School of Public Health
Share:
Change text size:
smaller

default

bigger